Literature DB >> 20961854

Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.

Jolanta Grembecka1, Amalia M Belcher, Thomas Hartley, Tomasz Cierpicki.   

Abstract

Chromosomal translocations targeting the mixed lineage leukemia (MLL) gene result in MLL fusion proteins that are found in aggressive human acute leukemias. Disruption of MLL by such translocations leads to overexpression of Hox genes, resulting in a blockage of hematopoietic differentiation that ultimately leads to leukemia. Menin, which directly binds MLL, has been identified as an essential oncogenic co-factor required for the leukemogenic activity of MLL fusion proteins. Here, we characterize the molecular basis of the MLL-menin interaction. Using (13)C-detected NMR experiments, we have mapped the residues within the intrinsically unstructured fragment of MLL that are required for binding to menin. Interestingly, we found that MLL interacts with menin with a nanomolar affinity (K(d) ∼ 10 nM) through two motifs, MBM1 and MBM2 (menin binding motifs 1 and 2). These motifs are located within the N-terminal 43-amino acid fragment of MLL, and the MBM1 represents a high affinity binding motif. Using alanine scanning mutagenesis of MBM1, we found that the hydrophobic residues Phe(9), Pro(10), and Pro(13) are most critical for binding. Furthermore, based on exchange-transferred nuclear Overhauser effect measurements, we established that MBM1 binds to menin in an extended conformation. In a series of competition experiments we showed that a peptide corresponding to MBM1 efficiently dissociates the menin-MLL complex. Altogether, our work establishes the molecular basis of the menin interaction with MLL and MLL fusion proteins and provides the necessary foundation for development of small molecule inhibitors targeting this interaction in leukemias with MLL translocations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961854      PMCID: PMC3003368          DOI: 10.1074/jbc.M110.172783

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Exchange-transferred NOE spectroscopy and bound ligand structure determination.

Authors:  Carol Beth Post
Journal:  Curr Opin Struct Biol       Date:  2003-10       Impact factor: 6.809

2.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 3.  When epigenetics kills: MLL fusion proteins in leukemia.

Authors:  Robert K Slany
Journal:  Hematol Oncol       Date:  2005-03       Impact factor: 5.271

4.  Interaction of MLL amino terminal sequences with menin is required for transformation.

Authors:  Corrado Caslini; Zhaohai Yang; Mohamad El-Osta; Thomas A Milne; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

5.  Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins.

Authors:  Wolfgang Bermel; Ivano Bertini; Isabella C Felli; Yong-Min Lee; Claudio Luchinat; Roberta Pierattelli
Journal:  J Am Chem Soc       Date:  2006-03-29       Impact factor: 15.419

6.  H-start for exclusively heteronuclear NMR spectroscopy: the case of intrinsically disordered proteins.

Authors:  Wolfgang Bermel; Ivano Bertini; Veronika Csizmok; Isabella C Felli; Roberta Pierattelli; Peter Tompa
Journal:  J Magn Reson       Date:  2009-03-04       Impact factor: 2.229

7.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Authors:  Ya-Xiong Chen; Jizhou Yan; Karen Keeshan; Anthony T Tubbs; Haoren Wang; Albert Silva; Eric J Brown; Jay L Hess; Warren S Pear; Xianxin Hua
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

8.  MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Authors:  Austin T Thiel; Peter Blessington; Tao Zou; Danielle Feather; Xinjiang Wu; Jizhou Yan; Hui Zhang; Zuguo Liu; Patricia Ernst; Gary A Koretzky; Xianxin Hua
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

9.  Global and Hox-specific roles for the MLL1 methyltransferase.

Authors:  Matthew G Guenther; Richard G Jenner; Brett Chevalier; Tatsuya Nakamura; Carlo M Croce; Eli Canaani; Richard A Young
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-07       Impact factor: 11.205

Review 10.  The role of the MLL gene in infant leukemia.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

View more
  37 in total

1.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.

Authors:  Dmitry Borkin; Szymon Klossowski; Jonathan Pollock; Hongzhi Miao; Brian M Linhares; Katarzyna Kempinska; Zhuang Jin; Trupta Purohit; Bo Wen; Miao He; Duxin Sun; Tomasz Cierpicki; Jolanta Grembecka
Journal:  J Med Chem       Date:  2018-05-23       Impact factor: 7.446

3.  Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.

Authors:  Marcelo J Murai; Maksymilian Chruszcz; Gireesh Reddy; Jolanta Grembecka; Tomasz Cierpicki
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

Review 4.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

5.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

6.  Detection of disordered regions in globular proteins using ¹³C-detected NMR.

Authors:  Felicia L V Gray; Marcelo J Murai; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Protein Sci       Date:  2012-12       Impact factor: 6.725

Review 7.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

Review 8.  The role of HTS in drug discovery at the University of Michigan.

Authors:  Martha J Larsen; Scott D Larsen; Andrew Fribley; Jolanta Grembecka; Kristoff Homan; Anna Mapp; Andrew Haak; Zaneta Nikolovska-Coleska; Jeanne A Stuckey; Duxin Sun; David H Sherman
Journal:  Comb Chem High Throughput Screen       Date:  2014-03       Impact factor: 1.339

9.  Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.

Authors:  Katarzyna Kempinska; Bhavna Malik; Dmitry Borkin; Szymon Klossowski; Shirish Shukla; Hongzhi Miao; Jingya Wang; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

10.  Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).

Authors:  Dmitry Borkin; Jonathan Pollock; Katarzyna Kempinska; Trupta Purohit; Xiaoqin Li; Bo Wen; Ting Zhao; Hongzhi Miao; Shirish Shukla; Miao He; Duxin Sun; Tomasz Cierpicki; Jolanta Grembecka
Journal:  J Med Chem       Date:  2016-01-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.